Complicated Urinary Tract Infections (cUTIs) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major complicated urinary tract infections (cUTIs) markets are expected to exhibit a CAGR of 5.6% during 2024-2034.
The complicated urinary tract infections (cUTIs) market has been comprehensively analyzed in IMARC's new report titled "Complicated Urinary Tract Infections (cUTIs) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Complicated urinary tract infections (cUTIs) are a subset of UTIs that typically occur in patients with functional or structural abnormalities of the urinary system or in those with underlying health issues, making treatment more challenging. Symptoms of these conditions can be severe and may include fever, chills, flank pain, frequent and urgent urination, cloudy or bloody urine, and a general feeling of illness. Individuals suffering from cUTIs often have underlying medical ailments or anatomical issues that predispose them to these infections, such as kidney stones, urinary catheters, or a compromised immune system. Diagnosing cUTIs involves a thorough medical history, physical examination, and urinalysis to detect the presence of bacteria and white blood cells in the urine. Additionally, urine cultures are commonly performed to identify the specific bacteria responsible for the infection and determine their susceptibility to antibiotics. Imaging studies, such as ultrasound or CT scans, may also be necessary to assess the extent of the disease and any anatomical abnormalities contributing to the condition.
The escalating prevalence of drug-resistant pathogens, which result in persistent and severe infections within the urinary system, is primarily driving the complicated urinary tract infections (cUTIs) market. In addition to this, the inflating utilization of effective medications, such as broad-spectrum antibiotics, carbapenems, and aminoglycosides, to combat these complex conditions and prevent severe complications is also creating a positive outlook for the market. Moreover, the widespread adoption of non-pharmacological strategies, including hydration therapy and urinary catheter management, which aim to enhance patient comfort and minimize the risk of recurrent infections, is further bolstering the market growth. Apart from this, the rising usage of advanced diagnostic tools, since they ensure timely and accurate identification of causative pathogens, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of immunotherapy approaches that work by leveraging the body's own immune system to battle persistent infections without inducing antibiotic resistance is also augmenting the market growth. Furthermore, the increasing application of targeted gene therapies, given their premise of specifically addressing the genetic vulnerabilities of pathogenic bacteria, is expected to drive the complicated urinary tract infections (cUTIs) market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the complicated urinary tract infections (cUTIs) market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for complicated urinary tract infections (cUTIs) and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the complicated urinary tract infections (cUTIs) market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the complicated urinary tract infections (cUTIs) market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the complicated urinary tract infections (cUTIs) market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current complicated urinary tract infections (cUTIs) marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report
Key Questions Answered in this Report:
Market Insights
How has the complicated urinary tract infections (cUTIs) market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the complicated urinary tract infections (cUTIs) market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the complicated urinary tract infections (cUTIs) market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of complicated urinary tract infections (cUTIs) across the seven major markets?
What is the number of prevalent cases (2018-2034) of complicated urinary tract infections (cUTIs) by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of complicated urinary tract infections (cUTIs) by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with complicated urinary tract infections (cUTIs) across the seven major markets?
What is the size of the complicated urinary tract infections (cUTIs) patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of complicated urinary tract infections (cUTIs)?
What will be the growth rate of patients across the seven major markets?
Complicated Urinary Tract Infections (cUTIs): Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for complicated urinary tract infections (cUTIs) drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the complicated urinary tract infections (cUTIs) market?
What are the key regulatory events related to the complicated urinary tract infections (cUTIs) market?
What is the structure of clinical trial landscape by status related to the complicated urinary tract infections (cUTIs) market?
What is the structure of clinical trial landscape by phase related to the complicated urinary tract infections (cUTIs) market?
What is the structure of clinical trial landscape by route of administration related to the complicated urinary tract infections (cUTIs) market?
The complicated urinary tract infections (cUTIs) market has been comprehensively analyzed in IMARC's new report titled "Complicated Urinary Tract Infections (cUTIs) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Complicated urinary tract infections (cUTIs) are a subset of UTIs that typically occur in patients with functional or structural abnormalities of the urinary system or in those with underlying health issues, making treatment more challenging. Symptoms of these conditions can be severe and may include fever, chills, flank pain, frequent and urgent urination, cloudy or bloody urine, and a general feeling of illness. Individuals suffering from cUTIs often have underlying medical ailments or anatomical issues that predispose them to these infections, such as kidney stones, urinary catheters, or a compromised immune system. Diagnosing cUTIs involves a thorough medical history, physical examination, and urinalysis to detect the presence of bacteria and white blood cells in the urine. Additionally, urine cultures are commonly performed to identify the specific bacteria responsible for the infection and determine their susceptibility to antibiotics. Imaging studies, such as ultrasound or CT scans, may also be necessary to assess the extent of the disease and any anatomical abnormalities contributing to the condition.
The escalating prevalence of drug-resistant pathogens, which result in persistent and severe infections within the urinary system, is primarily driving the complicated urinary tract infections (cUTIs) market. In addition to this, the inflating utilization of effective medications, such as broad-spectrum antibiotics, carbapenems, and aminoglycosides, to combat these complex conditions and prevent severe complications is also creating a positive outlook for the market. Moreover, the widespread adoption of non-pharmacological strategies, including hydration therapy and urinary catheter management, which aim to enhance patient comfort and minimize the risk of recurrent infections, is further bolstering the market growth. Apart from this, the rising usage of advanced diagnostic tools, since they ensure timely and accurate identification of causative pathogens, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of immunotherapy approaches that work by leveraging the body's own immune system to battle persistent infections without inducing antibiotic resistance is also augmenting the market growth. Furthermore, the increasing application of targeted gene therapies, given their premise of specifically addressing the genetic vulnerabilities of pathogenic bacteria, is expected to drive the complicated urinary tract infections (cUTIs) market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the complicated urinary tract infections (cUTIs) market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for complicated urinary tract infections (cUTIs) and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the complicated urinary tract infections (cUTIs) market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the complicated urinary tract infections (cUTIs) market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the complicated urinary tract infections (cUTIs) market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current complicated urinary tract infections (cUTIs) marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report
Key Questions Answered in this Report:
Market Insights
How has the complicated urinary tract infections (cUTIs) market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the complicated urinary tract infections (cUTIs) market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the complicated urinary tract infections (cUTIs) market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of complicated urinary tract infections (cUTIs) across the seven major markets?
What is the number of prevalent cases (2018-2034) of complicated urinary tract infections (cUTIs) by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of complicated urinary tract infections (cUTIs) by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with complicated urinary tract infections (cUTIs) across the seven major markets?
What is the size of the complicated urinary tract infections (cUTIs) patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of complicated urinary tract infections (cUTIs)?
What will be the growth rate of patients across the seven major markets?
Complicated Urinary Tract Infections (cUTIs): Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for complicated urinary tract infections (cUTIs) drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the complicated urinary tract infections (cUTIs) market?
What are the key regulatory events related to the complicated urinary tract infections (cUTIs) market?
What is the structure of clinical trial landscape by status related to the complicated urinary tract infections (cUTIs) market?
What is the structure of clinical trial landscape by phase related to the complicated urinary tract infections (cUTIs) market?
What is the structure of clinical trial landscape by route of administration related to the complicated urinary tract infections (cUTIs) market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 COMPLICATED URINARY TRACT INFECTIONS (CUTIS) - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (?2018-2023?) and Forecast (?2024-2034?)
4.4 Market Overview (?2018-2023?) and Forecast (?2024-2034?)
4.5 Competitive Intelligence
5 COMPLICATED URINARY TRACT INFECTIONS (CUTIS) - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 COMPLICATED URINARY TRACT INFECTIONS (CUTIS) - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (?2018-2023?)
7.2.2 Epidemiology Forecast (?2024-2034?)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (?2018-2023?)
7.3.2 Epidemiology Forecast (?2024-2034?)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (?2018-2023?)
7.4.2 Epidemiology Forecast (?2024-2034?)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (?2018-2023?)
7.5.2 Epidemiology Forecast (?2024-2034?)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (?2018-2023?)
7.6.2 Epidemiology Forecast (?2024-2034?)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (?2018-2023?)
7.7.2 Epidemiology Forecast (?2024-2034?)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (?2018-2023?)
7.8.2 Epidemiology Forecast (?2024-2034?)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (?2018-2023?)
7.9.2 Epidemiology Forecast (?2024-2034?)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 COMPLICATED URINARY TRACT INFECTIONS (CUTIS) - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 COMPLICATED URINARY TRACT INFECTIONS (CUTIS) - UNMET NEEDS
10 COMPLICATED URINARY TRACT INFECTIONS (CUTIS) - KEY ENDPOINTS OF TREATMENT
11 COMPLICATED URINARY TRACT INFECTIONS (CUTIS) - MARKETED PRODUCTS
11.1 List of Complicated Urinary Tract Infections (cUTIs) Marketed Drugs Across the Top 7 Markets
11.1.1 Recarbrio (Cilastatin/Imipenem/Relebactam) - Merck Sharp and Dohme
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Zemdri (Plazomicin) - Cipla
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Fetroja (Cefiderocol) - Shionogi
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Zerbaxa (Ceftolozane/tazobactam ) - Merck Sharp & Dohme
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Vabomere (Meropenem/vaborbactam) - Melinta Therapeutics
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 COMPLICATED URINARY TRACT INFECTIONS (CUTIS) - PIPELINE DRUGS
12.1 List of Complicated Urinary Tract Infections (cUTIs) Pipeline Drugs Across the Top 7 Markets
12.1.1 TBPM PI HBr - Spero Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Cefepime/zidebactam - Wockhardt
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Cefepime/enmetazobactam - Allecra Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Cefepime/Taniborbactam - VenatoRx Pharmaceuticals
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 ZTI-01 - Nabriva Therapeutics
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. COMPLICATED URINARY TRACT INFECTIONS (CUTIS) - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. COMPLICATED URINARY TRACT INFECTIONS (CUTIS) – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 COMPLICATED URINARY TRACT INFECTIONS (CUTIS) - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Complicated Urinary Tract Infections (cUTIs) - Market Size
15.2.1.1 Market Size (?2018-2023?)
15.2.1.2 Market Forecast (?2024-2034?)
15.2.2 Complicated Urinary Tract Infections (cUTIs) - Market Size by Therapies
15.2.2.1 Market Size by Therapies (?2018-2023?)
15.2.2.2 Market Forecast by Therapies (?2024-2034?)
15.3 Market Scenario - United States
15.3.1 Complicated Urinary Tract Infections (cUTIs) - Market Size
15.3.1.1 Market Size (?2018-2023?)
15.3.1.2 Market Forecast (?2024-2034?)
15.3.2 Complicated Urinary Tract Infections (cUTIs) - Market Size by Therapies
15.3.2.1 Market Size by Therapies (?2018-2023?)
15.3.2.2 Market Forecast by Therapies (?2024-2034?)
15.3.3 Complicated Urinary Tract Infections (cUTIs) - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Complicated Urinary Tract Infections (cUTIs) - Market Size
15.4.1.1 Market Size (?2018-2023?)
15.4.1.2 Market Forecast (?2024-2034?)
15.4.2 Complicated Urinary Tract Infections (cUTIs) - Market Size by Therapies
15.4.2.1 Market Size by Therapies (?2018-2023?)
15.4.2.2 Market Forecast by Therapies (?2024-2034?)
15.4.3 Complicated Urinary Tract Infections (cUTIs) - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Complicated Urinary Tract Infections (cUTIs) - Market Size
15.5.1.1 Market Size (?2018-2023?)
15.5.1.2 Market Forecast (?2024-2034?)
15.5.2 Complicated Urinary Tract Infections (cUTIs) - Market Size by Therapies
15.5.2.1 Market Size by Therapies (?2018-2023?)
15.5.2.2 Market Forecast by Therapies (?2024-2034?)
15.5.3 Complicated Urinary Tract Infections (cUTIs) - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Complicated Urinary Tract Infections (cUTIs) - Market Size
15.6.1.1 Market Size (?2018-2023?)
15.6.1.2 Market Forecast (?2024-2034?)
15.6.2 Complicated Urinary Tract Infections (cUTIs) - Market Size by Therapies
15.6.2.1 Market Size by Therapies (?2018-2023?)
15.6.2.2 Market Forecast by Therapies (?2024-2034?)
15.6.3 Complicated Urinary Tract Infections (cUTIs) - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Complicated Urinary Tract Infections (cUTIs) - Market Size
15.7.1.1 Market Size (?2018-2023?)
15.7.1.2 Market Forecast (?2024-2034?)
15.7.2 Complicated Urinary Tract Infections (cUTIs) - Market Size by Therapies
15.7.2.1 Market Size by Therapies (?2018-2023?)
15.7.2.2 Market Forecast by Therapies (?2024-2034?)
15.7.3 Complicated Urinary Tract Infections (cUTIs) - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Complicated Urinary Tract Infections (cUTIs) - Market Size
15.8.1.1 Market Size (?2018-2023?)
15.8.1.2 Market Forecast (?2024-2034?)
15.8.2 Complicated Urinary Tract Infections (cUTIs) - Market Size by Therapies
15.8.2.1 Market Size by Therapies (?2018-2023?)
15.8.2.2 Market Forecast by Therapies (?2024-2034?)
15.8.3 Complicated Urinary Tract Infections (cUTIs) - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Complicated Urinary Tract Infections (cUTIs) - Market Size
15.9.1.1 Market Size (?2018-2023?)
15.9.1.2 Market Forecast (?2024-2034?)
15.9.2 Complicated Urinary Tract Infections (cUTIs) - Market Size by Therapies
15.9.2.1 Market Size by Therapies (?2018-2023?)
15.9.2.2 Market Forecast by Therapies (?2024-2034?)
15.9.3 Complicated Urinary Tract Infections (cUTIs) - Access and Reimbursement Overview
16 COMPLICATED URINARY TRACT INFECTIONS (CUTIS) - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 COMPLICATED URINARY TRACT INFECTIONS (CUTIS) MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 COMPLICATED URINARY TRACT INFECTIONS (CUTIS) MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 COMPLICATED URINARY TRACT INFECTIONS (CUTIS) - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (?2018-2023?) and Forecast (?2024-2034?)
4.4 Market Overview (?2018-2023?) and Forecast (?2024-2034?)
4.5 Competitive Intelligence
5 COMPLICATED URINARY TRACT INFECTIONS (CUTIS) - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 COMPLICATED URINARY TRACT INFECTIONS (CUTIS) - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (?2018-2023?)
7.2.2 Epidemiology Forecast (?2024-2034?)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (?2018-2023?)
7.3.2 Epidemiology Forecast (?2024-2034?)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (?2018-2023?)
7.4.2 Epidemiology Forecast (?2024-2034?)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (?2018-2023?)
7.5.2 Epidemiology Forecast (?2024-2034?)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (?2018-2023?)
7.6.2 Epidemiology Forecast (?2024-2034?)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (?2018-2023?)
7.7.2 Epidemiology Forecast (?2024-2034?)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (?2018-2023?)
7.8.2 Epidemiology Forecast (?2024-2034?)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (?2018-2023?)
7.9.2 Epidemiology Forecast (?2024-2034?)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 COMPLICATED URINARY TRACT INFECTIONS (CUTIS) - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 COMPLICATED URINARY TRACT INFECTIONS (CUTIS) - UNMET NEEDS
10 COMPLICATED URINARY TRACT INFECTIONS (CUTIS) - KEY ENDPOINTS OF TREATMENT
11 COMPLICATED URINARY TRACT INFECTIONS (CUTIS) - MARKETED PRODUCTS
11.1 List of Complicated Urinary Tract Infections (cUTIs) Marketed Drugs Across the Top 7 Markets
11.1.1 Recarbrio (Cilastatin/Imipenem/Relebactam) - Merck Sharp and Dohme
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Zemdri (Plazomicin) - Cipla
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Fetroja (Cefiderocol) - Shionogi
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Zerbaxa (Ceftolozane/tazobactam ) - Merck Sharp & Dohme
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Vabomere (Meropenem/vaborbactam) - Melinta Therapeutics
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 COMPLICATED URINARY TRACT INFECTIONS (CUTIS) - PIPELINE DRUGS
12.1 List of Complicated Urinary Tract Infections (cUTIs) Pipeline Drugs Across the Top 7 Markets
12.1.1 TBPM PI HBr - Spero Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Cefepime/zidebactam - Wockhardt
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Cefepime/enmetazobactam - Allecra Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Cefepime/Taniborbactam - VenatoRx Pharmaceuticals
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 ZTI-01 - Nabriva Therapeutics
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. COMPLICATED URINARY TRACT INFECTIONS (CUTIS) - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. COMPLICATED URINARY TRACT INFECTIONS (CUTIS) – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 COMPLICATED URINARY TRACT INFECTIONS (CUTIS) - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Complicated Urinary Tract Infections (cUTIs) - Market Size
15.2.1.1 Market Size (?2018-2023?)
15.2.1.2 Market Forecast (?2024-2034?)
15.2.2 Complicated Urinary Tract Infections (cUTIs) - Market Size by Therapies
15.2.2.1 Market Size by Therapies (?2018-2023?)
15.2.2.2 Market Forecast by Therapies (?2024-2034?)
15.3 Market Scenario - United States
15.3.1 Complicated Urinary Tract Infections (cUTIs) - Market Size
15.3.1.1 Market Size (?2018-2023?)
15.3.1.2 Market Forecast (?2024-2034?)
15.3.2 Complicated Urinary Tract Infections (cUTIs) - Market Size by Therapies
15.3.2.1 Market Size by Therapies (?2018-2023?)
15.3.2.2 Market Forecast by Therapies (?2024-2034?)
15.3.3 Complicated Urinary Tract Infections (cUTIs) - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Complicated Urinary Tract Infections (cUTIs) - Market Size
15.4.1.1 Market Size (?2018-2023?)
15.4.1.2 Market Forecast (?2024-2034?)
15.4.2 Complicated Urinary Tract Infections (cUTIs) - Market Size by Therapies
15.4.2.1 Market Size by Therapies (?2018-2023?)
15.4.2.2 Market Forecast by Therapies (?2024-2034?)
15.4.3 Complicated Urinary Tract Infections (cUTIs) - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Complicated Urinary Tract Infections (cUTIs) - Market Size
15.5.1.1 Market Size (?2018-2023?)
15.5.1.2 Market Forecast (?2024-2034?)
15.5.2 Complicated Urinary Tract Infections (cUTIs) - Market Size by Therapies
15.5.2.1 Market Size by Therapies (?2018-2023?)
15.5.2.2 Market Forecast by Therapies (?2024-2034?)
15.5.3 Complicated Urinary Tract Infections (cUTIs) - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Complicated Urinary Tract Infections (cUTIs) - Market Size
15.6.1.1 Market Size (?2018-2023?)
15.6.1.2 Market Forecast (?2024-2034?)
15.6.2 Complicated Urinary Tract Infections (cUTIs) - Market Size by Therapies
15.6.2.1 Market Size by Therapies (?2018-2023?)
15.6.2.2 Market Forecast by Therapies (?2024-2034?)
15.6.3 Complicated Urinary Tract Infections (cUTIs) - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Complicated Urinary Tract Infections (cUTIs) - Market Size
15.7.1.1 Market Size (?2018-2023?)
15.7.1.2 Market Forecast (?2024-2034?)
15.7.2 Complicated Urinary Tract Infections (cUTIs) - Market Size by Therapies
15.7.2.1 Market Size by Therapies (?2018-2023?)
15.7.2.2 Market Forecast by Therapies (?2024-2034?)
15.7.3 Complicated Urinary Tract Infections (cUTIs) - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Complicated Urinary Tract Infections (cUTIs) - Market Size
15.8.1.1 Market Size (?2018-2023?)
15.8.1.2 Market Forecast (?2024-2034?)
15.8.2 Complicated Urinary Tract Infections (cUTIs) - Market Size by Therapies
15.8.2.1 Market Size by Therapies (?2018-2023?)
15.8.2.2 Market Forecast by Therapies (?2024-2034?)
15.8.3 Complicated Urinary Tract Infections (cUTIs) - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Complicated Urinary Tract Infections (cUTIs) - Market Size
15.9.1.1 Market Size (?2018-2023?)
15.9.1.2 Market Forecast (?2024-2034?)
15.9.2 Complicated Urinary Tract Infections (cUTIs) - Market Size by Therapies
15.9.2.1 Market Size by Therapies (?2018-2023?)
15.9.2.2 Market Forecast by Therapies (?2024-2034?)
15.9.3 Complicated Urinary Tract Infections (cUTIs) - Access and Reimbursement Overview
16 COMPLICATED URINARY TRACT INFECTIONS (CUTIS) - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 COMPLICATED URINARY TRACT INFECTIONS (CUTIS) MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 COMPLICATED URINARY TRACT INFECTIONS (CUTIS) MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
